INSMED INC

Insmed insider sales: Dr. Martina Flammer’s recent stock liquidation offers a window into executive liquidity, market perception and future strategic moves in the rare‑disease sector.

Insmed CEO’s January 20 trades show buying low at $30–$17 and selling high around $157–$161, revealing insider confidence in its rare‑disease pipeline and disciplined liquidity strategy for future growth.

Insmed CEO’s insider trades reveal a disciplined 10‑b‑5‑1 strategy—buying low, selling high—to fund rare‑disease R&D, boost liquidity, and signal confidence for investors and payers alike.